Advaxis Appoints Dr. Bradley Monk as Lead Cervical Cancer Advisor
Feb 01, 2016 13:05 pm UTC| Business
PRINCETON, N.J., Feb. 01, 2016 -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced the appointment of Bradley J. Monk, MD, FACOG, FACS as Lead...
Feb 01, 2016 13:01 pm UTC| Business
NEWTOWN, Pa., Feb. 01, 2016 -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh...
Feb 01, 2016 13:00 pm UTC| Business
NEW YORK, Feb. 01, 2016 -- Evercel, Inc. (OTC:EVRC) has successfully closed the sale of the Printronix thermal printer business to TSC Auto ID Technology Co., Ltd (“TSC”). The transaction was structured as the sale of...
Feb 01, 2016 13:00 pm UTC| Business
MALVERN, Pa., Feb. 01, 2016 -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that the...
Quotient Limited to Report Third Quarter Fiscal 2016 Financial Results and Host Conference Call
Feb 01, 2016 13:00 pm UTC| Business
JERSEY, Channel Islands, Feb. 01, 2016 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ending December 31, 2015 will be...
Aduro Biotech Receives $22.4 Million in Clinical Development Milestone Payments From Janssen
Feb 01, 2016 13:00 pm UTC| Business
BERKELEY, Calif., Feb. 01, 2016 -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that the company received $22.4 million in clinical development milestone payments from Janssen Biotech, Inc., the company’s license...
Pacific Mercantile Bancorp Reports Fourth Quarter and Fiscal 2015 Operating Results
Feb 01, 2016 13:00 pm UTC| Business
Fourth Quarter Highlights Net income of $12.1 million, or $0.53 per shareTax benefit of $11.6 million attributable to the reversal of the valuation allowance associated with the Company's deferred tax assetTotal...